Rupert Sandbrink
Duesseldorf, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 26, 2026
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
Journal: Neurology
Published: July 17, 2025
Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus.
Journal: The British journal of dermatology
Published: March 12, 2025
Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: January 07, 2022
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.
Journal: Brain imaging and behavior
Published: August 30, 2018
The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.
Journal: British journal of clinical pharmacology
Published: January 16, 2018
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Journal: Neurology
Published: September 28, 2015
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Journal: Journal of neurology
Published: July 15, 2015
Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
Journal: Retina (Philadelphia, Pa.)
Published: January 27, 2015
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Journal: Neurology
Published: January 26, 2015
Last Updated: 09/26/2026